Location Scout Manager Soliris

alexion-soliris

Location Scout – Location Manager for advertising photography for Soliris (Alexion, Cheshire, CT)

Cambridge BioMarketing   Orphan   Specialty Marketing Agency

 

Advertising Agency: Cambridge Biomarketing (Cambridge, MA)

James Salzano Photography

 

Photographer: James Salzano Photography (NYC)

Meredith Burkholder   LinkedIn

 

Producer: Meredith Burkholder (NYC)

Wikipedia

 

Soliris (Eculizumab) – Wikipedia

Eculizumab (INN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. Eculizumab has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and sometimes life threatening disease of the blood, and was first approved for this indication. It was also approved for atypical hemolytic-uremic syndrome (aHUS), a disease that causes abnormal blood clots to form in the kidneys, near the end of 2011.

Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that specifically binds to the complement protein C5, inhibiting its cleavage by the C5 convertase which prevents the generation of the terminal complement complex C5b-9. It is this terminal complement complex that causes intravascular hemolysis in people with (PNH).

Eculizumab is a product of Alexion Pharmaceuticals and was approved by the United States Food and Drug Administration (FDA) on March 16, 2007 and the European Medicines Agency on June 20, 2007.
According to Forbes magazine, Soliris, at $409,500 a year, is the world’s single most expensive drug.